BCL2L1 and cancer: Molecular docking studies were conducted to examine the binding interactions between six selected compounds (1–6) and the active sites of 10 target proteins (BCL-2, BCL-XL, caspase 3, caspase 9, CDK2, CDK6, EGFR, VEGFR, p53, and PARP-1) implicated in the cancer-related pathways.